Evaluation of effects of Pantoprazole against Doxorubicin-induced cardiotoxicity in rats

Abstract

Introduction: Doxorubicin is a drug used in the treatment of various cancers, but its use has been limited due to various complications, most notably cardiac toxicity. Pantoprazole is a drug that has ability to inhibit H + ATPase enzyme at high concentrations, which prevents the removal of hydrogen ions from cancer cells. Aim: To study the effect of pantoprazole on doxorubicin induced cardiomyopathy in rats Materials and Methods We randomly divided 30 rats into 5 groups of 6. The control group and DOX group received respectively six ip injections of normal saline and doxorubicin (2mg/kg ip to achieve a total dose of 12mg/kg). The 3th (DP100) group received 100mg/kg pantoprazole and two hours later 2 mg/kg doxorubicin with six intraperitoneal injections. The 4th (DP200) group received 200 mg/kg pantoprazole and two hours later 2 mg/kg doxorubicin with six intraperitoneal injections .The 5th (Pant) group received 200mg/kg pantoprazole with six intraperitoneal Injections. Results: DOX injection in rats caused changes in ECG pattern and hemodynamic and histological parameters (p <0.05). Concurrent injections of both doxorubicin and pantoprazole have improved some of the cardiac parameters, but pantoprazole has not been able to reduce the perceptible and acceptable side effects of doxorubicin. Conclusion: Using of pantoprazole with doxorubicin cannot reduce cardiac complications of DOX, but it has no adverse effects on the cardiovascular effects of doxorubicin and, in a few cases, has improved cardiac conditions and, however, simultaneously use of these two drugs leads to an increase in synergistic effect and increases the effect of doxorubicin on cancer cells, therefore, absence of adverse effects on the complications of doxorubicin cardiomyopathy by pantoprazole and, sometimes, improvement of some conditions, is a positive result for the co-administration of these two drugs together for cancer treatment.